Researchers tracked real-world data from 600 TAVR patients, following each one for approximately five years. Survival rates were similar for men and women early on, but then women started experiencing better outcomes after three years.
Using a DCB that releases sirolimus over an extended period of time appears to be both safe and effective when treating patients who present with NSTEMI or unstable angina.
The popular drugs, originally developed to treat diabetes, were also associated with an improved survival rate. Benefits were seen in patients who did and did not lose significant weight as a result of treatment.
Published in Clinical Imaging, the responses indicate that Trump administration policies have made it more difficult to acquire funding and collaborate with other researchers.
Veteran cardiologist Harlan M. Krumholz, MD, has a long history in medical research as both an author and an editor. He and his team want to review manuscripts quickly and publish a wide variety of voices.
Vivek Reddy, MD, was involved in most of the late-breaking pulsed field ablation trials at Heart Rhythm 2024. He spoke to Cardiovascular Business at the conference about those trials and what they mean going forward.
It's clear that advanced AI algorithms will radically transform care for TAVR patients in the years ahead. For now, however, certain AI models may require too much data to be helpful on a consistent basis.
As a person’s concentration dwindles during resting state or task-based sequences, the resultant brain activity observed on imaging could be misleading.
